Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Odonate Therapeutics Inc (ODT)

Odonate Therapeutics Inc (ODT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 884,499
  • Shares Outstanding, K 32,187
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,960 K
  • 60-Month Beta 1.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.07
  • Number of Estimates 1
  • High Estimate -1.07
  • Low Estimate -1.07
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -9.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.18 +5.11%
on 09/16/19
35.17 -18.77%
on 08/21/19
-5.95 (-17.24%)
since 08/20/19
3-Month
26.26 +8.80%
on 06/21/19
43.75 -34.70%
on 08/02/19
+1.49 (+5.50%)
since 06/20/19
52-Week
11.54 +147.57%
on 12/28/18
43.75 -34.70%
on 08/02/19
+8.20 (+40.26%)
since 09/20/18

Most Recent Stories

More News
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

JAZZ : 129.21 (-0.03%)
REPH : 11.84 (+0.77%)
ODT : 28.57 (+3.97%)
HJLI : 0.95 (+3.26%)
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust, Comtech Telecommunications, and Odonate Therapeutics -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM),...

NEM : 39.84 (+1.14%)
JNJ : 131.65 (+1.18%)
PTLA : 30.37 (+0.50%)
CMTL : 29.74 (+1.26%)
MRT : 11.03 (-1.43%)
ODT : 28.57 (+3.97%)
Detailed Research: Economic Perspectives on Omnicom Group, Venator Materials, Leidos, International Flavors & Fragrances, Odonate Therapeutics, and Aqua America -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omnicom Group Inc. (NYSE:OMC),...

OMC : 77.87 (-0.80%)
WTR : 44.42 (+0.43%)
IFF : 120.17 (-2.19%)
VNTR : 2.96 (+2.07%)
ODT : 28.57 (+3.97%)
LDOS : 86.33 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade ODT with:

Business Summary

Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic...

See More

Key Turning Points

2nd Resistance Point 29.85
1st Resistance Point 29.21
Last Price 28.57
1st Support Level 27.67
2nd Support Level 26.77

See More

52-Week High 43.75
Fibonacci 61.8% 31.45
Last Price 28.57
Fibonacci 50% 27.65
Fibonacci 38.2% 23.84
52-Week Low 11.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar